2017 American Transplant Congress
Population Pharmacokinetic Profiling of Tacrolimus in Renal Transplant Recipients (RTRs) Taking Diltiazem.
Background: Over the past 6 years we have prospectively used pharmacokinetic (PK) profiling of Tacrolimus (TAC) in “stable” RTR's to individualise future dosing. This study…2017 American Transplant Congress
Optimization of Extended-Release Tacrolimus Dose with Mycophenolate Mofetile Based Immunosuppression in De Novo Kidney Transplant Recipients: 2 Years Outcome.
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well determined. We have validated the institutional…2017 American Transplant Congress
One Year Outcomes of Low-Dose vs Very Low-Dose Extended-Release Tacrolimus/Mycophenolate mofetil in De Novo Kidney Transplantation: A Multi-Center Randomized Controlled Trial.
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has now been widely accepted in kidney transplant field. However, the optimal dosage for TACER is still not known.Patients…2017 American Transplant Congress
Comparison of Long Term Renal Function Outcomes for Everolimus (EVR) vs. Sirolimus (SIR) vs. Mycophenolate Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant (Ktx).
MPA or mammalian target of rapamycin inhibitors (mTORi [EVR or SIR]) in combination with calcineurin inhibitors (CNI, tacrolimus [TAC] or cyclosporine) are used for maintenance…2017 American Transplant Congress
The Associations Between Immunosuppression Use, Loss of Medicare and Kidney Allograft Outcomes.
Medicare coverage for kidney transplant recipients aged <65 years in the US ends 3 years posttransplant, but a significant proportion of recipients remain on Medicare…2017 American Transplant Congress
Determinants of Successful Use of Sirolimus in Renal Transplantation.
Sirolimus (SLR) is an established component in the immunosuppressive treatment after renal transplantation.The side effects of SLR differ from other immunosuppressants and may limit its…2017 American Transplant Congress
A Novel, Dose-Adjusted Tacrolimus Trough Concentration (TTC) Model for Prediction and Variance Estimation.
Given that a high tacrolimus (tac) intrapatient variability (IPV) increases the risk for a poor kidney transplant (tx) outcome, some experts advocate routine IPV monitoring…2017 American Transplant Congress
Once-Daily versus Twice-Daily Tacrolimus in Living Kidney Transplantation: A Multicenter, Parallel Group, Open-Label, 5-Year, Randomized Non-Inferiority Trial.
Background:Tacrolimus (TAC)-based induction therapy appears to be the standard immunosuppressive regimen for most kidney transplantation recipients (KTRs). TAC is available as a twice-daily (TAC-BID) and…2017 American Transplant Congress
Impact of Polymorphisms of UGT 1 A9 on the Prognosis of Renal Transplant Patients. Association with Digestive Tumors.
Nephrologist, Hospital Clinico San Carlos, Madrid, Spain
The aim of this study was to evaluate the distribution of UGT1A9 promoter region T-275A and C-2152T single nucleotide polymorphisms (SNPs) in stable transplant patients…2017 American Transplant Congress
Steroid Withdrawal Using Everolimus in Maintenance Kidney Transplant Recipients with Post-Transplant Diabetes Mellitus.
Background: Although steroid withdrawal from conventional immunosuppressive therapy has been attempted to ameliorate various complications, especially diabetes mellitus (DM), in kidney transplant recipients, a steroid-sparing…
American Transplant Congress abstracts